Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
14 Leser
Artikel bewerten:
(0)

Primary Sclerosing Cholangitis (PSC) Market Pipeline Report for H2 2015

PUNE, India, December 15, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Primary Sclerosing Cholangitis - Pipeline Review, H2 2015" market research report to its store. The report provides an overview of the Primary Sclerosing Cholangitis's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Company Profiles discussed in this report includes Biotie Therapies Corp., ChemoCentryx, Inc., Dr. Falk Pharma GmbH, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc. and Shire Plc. Drugs Profiles discussed in this report includes BTT-1023, CCX-507, norursodeoxycholic acid, obeticholic acid, SHP-625 and simtuzumab. Complete report on H2 2015 pipeline review of Primary Sclerosing Cholangitis with 17 market data tables and 13 figures, spread across 51 pages is available at http://www.rnrmarketresearch.com/primary-sclerosing-cholangitis-pipeline-review-h2-2015-market-report.html .

This report provides comprehensive information on the therapeutic development for Primary Sclerosing Cholangitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Sclerosing Cholangitis and special features on late-stage and discontinued projects.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for Primary Sclerosing Cholangitis and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Primary Sclerosing Cholangitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Primary Sclerosing Cholangitis pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=411462 .

Another newly published market research report titled on Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. Respiratory Syncytial Virus (RSV) Infections market research report is available at http://www.rnrmarketresearch.com/respiratory-syncytial-virus-rsv-infections-pipeline-review-h2-2015-market-report.html .

More reports on Therapeutics are available at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cardiovascular-therapeutics .

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@rnrmarketresearch.com


Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.